AVDL
Price
$12.71
Change
+$0.11 (+0.87%)
Updated
Feb 23, 2:37 PM EST
20 days until earnings call
CYTH
Price
$1.70
Change
+$0.01 (+0.59%)
Updated
Feb 23, 2:42 PM EST
17 days until earnings call
Ad is loading...

Compare trend and price AVDL vs CYTH

Header iconAVDL vs CYTH Comparison
Open Charts AVDL vs CYTHBanner chart's image
Avadel Pharmaceuticals
Price$12.71
Change+$0.11 (+0.87%)
Volume$100
CapitalizationN/A
Cyclo Therapeutics
Price$1.70
Change+$0.01 (+0.59%)
Volume$290
CapitalizationN/A
View a ticker or compare two or three
AVDL vs CYTH Comparison Chart

Loading...

AVDLDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CYTHDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
AVDL vs. CYTH commentary
Feb 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVDL is a StrongSell and CYTH is a Buy.

COMPARISON
Comparison
Feb 23, 2024
Stock price -- (AVDL: $12.60 vs. CYTH: $1.69)
Brand notoriety: AVDL: Notable vs. CYTH: Not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: AVDL: 98% vs. CYTH: 32%
Market capitalization -- AVDL: $1.13B vs. CYTH: $48.32M
AVDL [@Pharmaceuticals: Other] is valued at $1.13B. CYTH’s [@Pharmaceuticals: Other] market capitalization is $48.32M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $90.04B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $2.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVDL’s FA Score shows that 1 FA rating(s) are green whileCYTH’s FA Score has 0 green FA rating(s).

  • AVDL’s FA Score: 1 green, 4 red.
  • CYTH’s FA Score: 0 green, 5 red.
According to our system of comparison, AVDL is a better buy in the long-term than CYTH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVDL’s TA Score shows that 4 TA indicator(s) are bullish while CYTH’s TA Score has 5 bullish TA indicator(s).

  • AVDL’s TA Score: 4 bullish, 6 bearish.
  • CYTH’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, CYTH is a better buy in the short-term than AVDL.

Price Growth

AVDL (@Pharmaceuticals: Other) experienced а -11.27% price change this week, while CYTH (@Pharmaceuticals: Other) price change was +1.20% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.47%. For the same industry, the average monthly price growth was +0.85%, and the average quarterly price growth was +51.18%.

Reported Earning Dates

AVDL is expected to report earnings on May 06, 2024.

CYTH is expected to report earnings on May 14, 2024.

Industries' Descriptions

@Pharmaceuticals: Other (-0.47% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
A.I.dvisor published
a Summary for AVDL with price predictions.
OPEN
A.I.dvisor published
a Summary for CYTH with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
AVDL($1.13B) has a higher market cap than CYTH($48.3M). CYTH YTD gains are higher at: 6.289 vs. AVDL (-10.765). CYTH has higher annual earnings (EBITDA): -19.36M vs. AVDL (-146.1M). AVDL has more cash in the bank: 153M vs. CYTH (1.8M). CYTH has less debt than AVDL: CYTH (45.2K) vs AVDL (24M). AVDL has higher revenues than CYTH: AVDL (8.51M) vs CYTH (952K).
AVDLCYTHAVDL / CYTH
Capitalization1.13B48.3M2,344%
EBITDA-146.1M-19.36M755%
Gain YTD-10.7656.289-171%
P/E RatioN/AN/A-
Revenue8.51M952K894%
Total Cash153M1.8M8,491%
Total Debt24M45.2K53,097%
FUNDAMENTALS RATINGS
AVDL vs CYTH: Fundamental Ratings
AVDL
CYTH
OUTLOOK RATING
1..100
6177
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
64
Fair valued
PROFIT vs RISK RATING
1..100
31100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5441
P/E GROWTH RATING
1..100
52100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYTH's Valuation (64) in the null industry is in the same range as AVDL (83) in the Medical Specialties industry. This means that CYTH’s stock grew similarly to AVDL’s over the last 12 months.

AVDL's Profit vs Risk Rating (31) in the Medical Specialties industry is significantly better than the same rating for CYTH (100) in the null industry. This means that AVDL’s stock grew significantly faster than CYTH’s over the last 12 months.

AVDL's SMR Rating (100) in the Medical Specialties industry is in the same range as CYTH (100) in the null industry. This means that AVDL’s stock grew similarly to CYTH’s over the last 12 months.

CYTH's Price Growth Rating (41) in the null industry is in the same range as AVDL (54) in the Medical Specialties industry. This means that CYTH’s stock grew similarly to AVDL’s over the last 12 months.

AVDL's P/E Growth Rating (52) in the Medical Specialties industry is somewhat better than the same rating for CYTH (100) in the null industry. This means that AVDL’s stock grew somewhat faster than CYTH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVDLCYTH
RSI
ODDS (%)
Bullish Trend 2 days ago
71%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 25 days ago
84%
Bullish Trend 23 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
AVDLDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CYTHDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IEMGX9.900.15
+1.54%
Voya Multi-Manager Emerging Markets Eq I
ESEAX33.180.34
+1.04%
Eaton Vance Atlanta Capital Sel Eq A
PRFDX34.710.23
+0.67%
T. Rowe Price Equity Income
GSBIX25.040.12
+0.48%
Goldman Sachs Income Builder Instl
ASUAX12.82N/A
N/A
Virtus NFJ Global Sustainability A

AVDL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVDL has been loosely correlated with SIGA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if AVDL jumps, then SIGA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVDL
1D Price
Change %
AVDL100%
-0.63%
SIGA - AVDL
38%
Loosely correlated
-0.96%
EOLS - AVDL
25%
Poorly correlated
+0.77%
SSIC - AVDL
24%
Poorly correlated
+5.76%
NBIX - AVDL
23%
Poorly correlated
+2.08%
CYTH - AVDL
22%
Poorly correlated
+0.60%
More

CYTH and

Correlation & Price change

A.I.dvisor tells us that CYTH and ACB have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CYTH and ACB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTH
1D Price
Change %
CYTH100%
+0.60%
ACB - CYTH
24%
Poorly correlated
-4.41%
RDHL - CYTH
24%
Poorly correlated
-2.23%
AVDL - CYTH
22%
Poorly correlated
-0.63%
CGC - CYTH
22%
Poorly correlated
-1.74%
PTPI - CYTH
21%
Poorly correlated
+5.66%
More